Recombinant therapeutic proteins were introduced >20 years ago and now generate >$99 billion in annual revenue from a broad range of products, including monoclonal antibodies, growth factors, hormones, blood factors, interferons and enzymes 1 . For these biopharmaceuticals, CHO-derived cell lines are the preferred host expression systems because of their advantages in producing complex therapeutics and manufacturing adaptability. CHO cells can be genetically manipulated and grown either as adherent cells or in suspension. Methods for cell transfection, gene amplification and clone selection in CHO cells are well characterized and widely used. Furthermore, CHO cells have an established history of regulatory approval for recombinant protein expression. Most importantly, these cells perform humancompatible, post-translational modifications (e.g., glycosylation), thereby improving therapeutic efficacy, protein longevity and reducing safety concerns. Various cell-line engineering strategies have been developed for CHO cells to enhance post-translational modifications, such as antibody glycosylation and protein sialylation 2 . As a result, CHO cell lines now play a dominant role in bioprocessing research and the development of therapeutic biopharmaceuticals, delivering up to several grams per liter of these products in highly optimized production processes 3 .
A r t i c l e s is the length of the smallest contig (scaffold) S in the sorted list of all contigs (scaffolds) where the cumulative length from the largest contig to contig S is at least 50% of the total assembly length 8 ). The CHO-K1 genome size was estimated to be 2.6 Gb using the k-mer estimation method (Supplementary Figs. 1-3 for distributions of sequencing depth and GC content.).
To assign scaffolds to chromosomes, we isolated and amplified individual chromosomes from single molecules using a microfluidic device (Online Methods) 9 . Each chromosome preparation was amplified, barcoded and sequenced on an Illumina HiSeq(2000) (2 × 100 bp reads). The reads from each chromosome preparation were aligned to the assembled scaffolds and the frequency of paired-end reads aligning from each chromosome preparation was computed and normalized. Metrics derived from the normalized frequencies were used for assigning scaffolds to a particular chromosome preparation (Supplementary Notes). All of the longest scaffolds that represent 50% of the assembly (top N50 scaffolds) had chromosome reads mapping to them; 68% of the top N50 scaffolds could be unambiguously mapped to unique chromosome preparations ( Table 1) .
Different chromosomal counts have been reported for the CHO-K1 karyotype 10 , presumably due to its genomic instability. To find evidence of multiple or duplicate chromosomes across the 22 sample preparations, we used the frequency of the paired-end reads aligning from each chromosome preparation to compute the correlation between the N50 scaffolds (Supplementary Notes). Scaffolds that are from the same chromosome will be highly correlated owing to physical connection. Clustering of this correlation matrix revealed 21 large, discrete noninteracting blocks, which can be interpreted as the chromosomes containing the respective scaffolds ( Fig. 1a and Supplementary Notes). Consistent with this result, classical karyotyping found 21 chromosomes in CHO-K1 (Fig. 1b and Online Methods).
Repeat features in the CHO-K1 genome Approximately 37.79% of the CHO-K1 genome is made up of transposable elements, as estimated from a combination of de novo repeat identification using RepeatModeller and analysis against the Repbase library [11] [12] [13] . This fraction of repeats is comparable to that in the mouse genome (37%) and lower than that in the human genome (46%). These transposable elements were classified into various categories (Supplementary Tables 2-4 ). The fraction of tandem repeats in the CHO genome (2.7%) is similar to that in rat (2.9%) and mouse (3.3%) but higher than that in human (1.5%). In summary, the repeat features of the CHO genome are more similar to those of the rodent genomes than of the human genome. This observation is consistent with earlier reports in which the mouse and rat genomes were shown to have a higher fraction of repeats compared to other mammals, especially primates [14] [15] [16] .
Gene prediction and annotation
To predict genes in the CHO-K1 genome, we used a combination of de novo geneprediction programs and homology-based methods. The predicted gene models were reconciled using the GLEAN algorithm 17 . We also generated 10.8 Gb of transcriptome sequence data from exponentially growing CHO-K1 cells cultured in F-12K medium supplemented with 10% FBS, and used these data to improve gene prediction by suggesting additional transcribed genes in CHO-K1 that were missed by the gene prediction methods (Supplementary Tables 5 and 6) Table 12) ). When compared to human, mouse and rat, the distribution of CHO GO class assignments shows significant coverage (that is, >50% of the instances in mouse and significantly enriched, P < 0.01) of classes involved in translation, metabolism and Figure 1 Chromosomal assignment to scaffolds. (a) Chromosomal preparations from CHO-K1 were sequenced and the reads were aligned to the scaffolds. For each of the N50 scaffolds, a vector was used to represent the read alignments in the 22 preparations. Using this metric, a correlation matrix was generated between all the N50 scaffolds. Upon clustering the matrix, 21 clusters of highly correlated scaffolds emerged, suggesting that the scaffolds are associated with 21 chromosomes in CHO-K1. (b) Classical karyotyping of CHO-K1 reveals 21 chromosomes.
A r t i c l e s protein modification (Fig. 2) . On the other hand, classes for which few genes were identified (that is, <1% of the instances in human and mouse and significantly depleted, P < 0.01) included behavior, embryo development and anatomical structure morphogenesis. Taken together, the GO classes that had the least coverage in the CHO-K1 genome may be less relevant for a cell line (Fig. 2) .
CHO-K1 genes involved in protein glycosylation pathways
The therapeutic proteins secreted by CHO cells often include posttranslational modifications including N-or O-linked glycosylation. For some of these proteins, differential glycosylation can substantially affect functional activity and/or in vivo circulatory half-life 18 . Furthermore, such modifications can induce immune responses if they differ from native human glycans. Therefore a genome-scale assessment of CHO glycosylation is important in the understanding of CHO-derived glycoprotein quality.
Out of 300 human genes associated with glycan synthesis and degradation, only three genes (ALG13, CHST7 and CHST13) lack homologs in the CHO-K1 genome (Supplementary Table 13 ). As almost all glycosylation genes are found in CHO-K1, we expect that the expression and activities of these gene products are more important than their presence in the genome for determining the diversity of glycan structures on protein products in CHO. In RNA-Seq data for exponentially growing CHO-K1 cells, we detected about half of the predicted glycosylation genes (Fig. 3a) . N-glycan transferases, mannosyltransferases, sugar-nucleotide synthesis genes and hyaluronoglucosaminidases were enriched for expression or completely expressed. These classes are critical for constructing the core parts of the glycan chains or dictating glycan localization. The significantly depleted classes (P < 0.06) among the expressed fraction of genes included the sulfotransferases, fucosyltransferases and N-acetylgalactosamine (GalNAc) transferases.
Bisecting N-acetylglucosamine (GlcNAc) CHO cell lines often produce glycoforms similar to human glycans. However, CHO cells do not produce the bisecting GlcNAc branch, which is found on about 10% of human IgG glycoforms 19 . The CHO LEC10 cell line remedies this with a gain-of-function mutation that induces MGAT3 expression, coding for GnTIII/GlcNAcTIII, which adds the bisecting GlcNAc residue 20 . The fact that the LEC10 cell line gains this functionality suggests that the gene is present in the parent strain. Consistent with this, a homolog to this gene is found in the CHO-K1 genome but is not expressed (Fig. 3b,i) . Table 14 for the glycans fucosylated by each class). However, in the CHO-K1 transcriptome data, only fucosyltransferase 8 (FUT8) and the protein O-fucosyltransferases (POFUT1 and POFUT2) show expression. These add α(1,6)-linked fucose to N-linked glycans (see reaction F6Tg in Fig. 3b ,ii) or directly to serine/threonine residues, respectively. Indeed, suppression of FUT8 activity improves the quality of CHO-produced therapeutic antibodies, by removing fucose from the Fc oligosaccharides and altering its binding properties [21] [22] [23] . Furthermore, because the α(1,2), α(1,3) and α(1,4)-linked fucosyltransferases are not expressed, the Lewis and ABO blood group glycans will probably not be generated in this CHO-K1 cell-line.
Sialylation
Glycan sialylation can have an impact on the function, longevity and immunogenic effects of proteins. Sialic acids often are the terminal sugar on N-linked glycans. These sugars may increase the lifespan of glycoproteins in the circulatory system by covering the penultimate galactose, which otherwise would bind to the hepatocyte asialoglycoprotein receptor and subsequently be degraded 24 . The CHO-K1 genome has homologs to all six human ST3Gal enzymes, which form α(2,3) linkages of sialic acid to galactose. Moreover, these genes are expressed as well (Fig. 3b,iii) . Although homologs also exist for the human ST6Gal genes, which catalyze α(2,6) linkages of sialic acid to galactose, the transcriptome data show no evidence for ST6Gal gene expression. This is consistent with the observation that CHO cells do not normally show ST6Gal activity 19 , whereas terminal α(2,3)-linked sialic acid residues are abundant.
Genes involved in immunogenic responses
One challenge in therapeutic protein production is the avoidance of immunogenic responses 25, 26 that can arise from foreign glycan structures. For example, immunogenic responses can be induced by glycans harboring N-glycolylneuraminic acid (Neu5Gc), the hydroxylated derivative of the sialic acid N-acetylneuraminic acid (Neu5Ac). This hydroxylation is catalyzed by cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH), which is highly expressed and active in most mammals but not in humans 27 . Thus, the glycosylated proteins produced in non-human cell lines can induce an immune Fraction of all GO term annotations in the associated genome Figure 2 Comparative analysis of functional categories and gene content. For each GOslim biological process category, the fraction of all GO terms in that category is shown for human, mouse, rat and CHO genomes. GOslim classes that are significantly enriched and show the highest and lowest coverage of human and mouse genes in the CHO genome are highlighted in red (*) and green (**), respectively. P value cutoff and coverage in human and mouse were used to determine significance.
A r t i c l e s response in humans unless Neu5Gc production is controlled. Interestingly, although a CMAH homolog is found in the CHO-K1 genome, we did not detect any expression in this analysis (Fig. 3b,iv) . This result is consistent with the observation that CHO cell lines contain considerably lower levels of Neu5Gc sialylation in comparison to murine cell lines 28 . The antigen Gal-α(1,3)Gal can also elicit immunogenic responses in humans, as most individuals have anti-α-Gal antibodies 29 . The gene responsible for producing this epitope, glycoprotein α(1,3) galactosyltransferase (Ggta1), is not expressed in human, but is active in mouse. Thus, recombinant IgAs produced in murine cell lines are considerably different from human IgAs. CHO cells lack the sufficient enzymatic machinery to produce glycan structures with the α-Gal epitopes 30 , except in very small subpopulations 31 . Furthermore, IgAs produced in CHO cells are similar to human IgA and lack the α-Gal epitope 32 . Consistent with these findings, a homolog to mouse Ggta1 is present in the CHO-K1 genome but was not expressed (see Supplementary Notes for additional discussion on glycans with potential relevance to immunogenic responses).
Sulfotransferases involved in sulfation of glycosaminoglycans
Despite harboring homologs to human sulfotransferases in the genome, CHO-K1 does not express most of them (Fig. 3a) . These enzymes play important roles in the generation of heparan sulfate, which is known to be important for entry of viruses such as HIV 33 , adenoviruses 34 and herpes simplex virus (HSV) 35 . Interestingly, CHO-K1 has been used extensively to investigate the need for heparan sulfate in viral entry. Although CHO-K1 has heparan sulfate and chondroitin-4-sulfate, several mutants with reduced or no heparan sulfate have been produced by merely inhibiting a few enzymes 36 .
In the CHO-K1 genome, we identified homologs to most human heparan sulfate glucosamine O-sulfotransferases. Consistent with previous studies [37] [38] [39] [40] , we found that heparan sulfate glucosamine 2-O-sulfotransferases and heparan sulfate glucosamine 6-Osulfotransferases are expressed. However, no detectable expression was measured for heparan sulfate glucosamine 3-O-sulfotransferases (HS3ST), which make 3-O-sulfated heparan sulfate (important for HSV-1 entry 35 ; Fig. 4) . Although CHO-K1 is resistant to HSV-1 infection 35 , the addition of mouse genes encoding HS3ST to CHO-K1 cells renders them susceptible to HSV-1 infection 41 . This result suggests that CHO-K1 lacks HS3ST activity, which is consistent with the lack of detectable HS3ST expression in our study.
Global analysis of viral susceptibility genes in CHO-K1 genome Viral infections can contaminate cell culture processes, thus affecting the quality and yield of recombinant protein production. Hence, the property of resistance to viral infection demonstrated by CHO cells A r t i c l e s further contributes to their preferred choice as hosts for therapeutic protein production 42 . We next investigated this property using the CHO-K1 genome and transcriptome. Twelve independent studies were summarized to compile a list of human genes important for viral infection 43 . A total of 388 human genes that were identified in two or more of these independent studies were used for subsequent analysis. Among these, CHO-K1 homologs were not found for four genes (IL1A, SNRPC, MT1X and CD58). Moreover, 158 genes lacked detectable expression levels in the CHO-K1 transcriptome. Among the unexpressed genes, the most enriched GO-terms in the molecular function and biological process classes were glycoprotein binding, T-cell activation and macromolecular assembly (Supplementary Tables 15-17) . Many of these genes are either cell adhesion molecules (CAMs), important for viral entry and vesicular trafficking, or plasma membrane proteins involved in viral recognition. Furthermore, several histone proteins involved in nucleosome assembly do not show any detectable expression in the CHO-K1 transcriptome (Fig. 4a) .
HSV is a well-studied virus that is unable to infect CHO cells owing to the lack of entry receptors 44 . The CHO-K1 genome and transcriptome provide insights pertaining to these entry receptors and HSV infection (Fig. 4b) . HSV-1 is known to require the Nectin-1/HveC receptor (PVRL1) and herpes virus entry mediator (HveM) for entry into host cells. Although the CHO-K1 genome has homologs to both genes, expression was not detected. Integrins also are cellular receptors that regulate the cell-surface attachment and entry of viruses like HSV. Several integrin genes (e.g., ITGB3, ITGAV and ITGAM) do not show evidence of expression in the transcriptome data. This lack of expression of integrin genes in CHO cells has been documented previously 45, 46 . The epidermal growth factor receptor (EGFR) also plays a role in the entry of HSV-1 into CHO-K1 cells. Reports indicate that CHO cells expressing EGFR are susceptible to HSV infection, whereas the wild-type cells lacking EGFR expression are resistant 47 . Consistent with this observation, an EGFR homolog is in the CHO-K1 genome, but it is not expressed in the CHO-K1 transcriptome.
In addition to HSV, other viruses, such as pseudorabies virus, are blocked from infecting CHO cells at the level of viral penetration 48 . Receptors for other viruses like HIV and hepatitis B virus (HBV) are either missing in the CHO-K1 genome or lacking expression in the transcriptome. For instance, the CD4 glycoprotein is not expressed in CHO-K1, thereby blocking entry of HIV-1 into host cells. Similarly, we do not find evidence for the CD58 gene in the CHO-K1 genome. The expression levels of the CAM CD58 correlate with HBV infection severity 49 . Several other CAMs like CD48 and CD2 are also not expressed in the CHO-K1 transcriptome data. These proteins bind heparan sulfate and play an important role in viral infection 50 .
The resistance of CHO cells to viral infection is not limited to the regulation of viral entry. For instance, the restriction of Vaccinia virus replication in CHO cells is reported to occur because of the lack of the cowpox host range factor CP77. The absence of CP77 causes a rapid shutdown of viral protein synthesis machinery 51 . Consistent with this, the CHO-K1 genome does not encode this gene. DISCUSSION CHO-derived immortalized cell lines are the preferred host system for therapeutic protein production. CHO cell line engineering work has made incredible progress in optimizing products and titers by focusing on manipulating single genes 2 and selecting clones with desirable traits after various treatments (e.g., mutagenesis or media adjustment). This progress has been accomplished without the availability of genomic sequences. Here we present a publicly available annotated genome sequence for a CHO cell line, which represents yet another tool in the bioprocessing toolbox. It is not anticipated that this draft sequence will directly improve product titers to the extent achieved through careful screens in the past. However, the CHO-K1 genomic sequence will facilitate the design of targeted genetic manipulations to aid in cell line engineering (Fig. 5a) , help in the elucidation of components underlying poorly characterized phenotypes (Fig. 5b) and allow for more comprehensive deployment of ' omic tools for CHO-K1 and related cell lines (Fig. 5c) .
A genome-scale analysis of the glycosylation genes in the CHO-K1 genome identifies homologs to 99% of the human glycosylationassociated transcripts, with 53% of them expressed. The high coverage of homologs provides a unique opportunity for glycoform manipulation in CHO cells. Indeed, the high variability of gene silencing has led to the generation of the diverse selection of Lec mutant cell lines 20 . Moreover, it has been shown that clonal selection can lead to a subpopulation of CHO cells expressing genes like GGTA1, that were thought to be inactive 31 . This result suggests that many other unexpressed glycosylation genes in the CHO genome can be potentially activated or silenced to alter the repertoire of glycan structures from CHO cells (Fig. 5a) . In addition, the genome sequence will facilitate the development of genome-scale metabolic models for CHO cells. Such models allow for the assessment of the network-level effects of cell line treatments, and have been successful at predicting optimal designs for bioprocess optimization in prokaryotes [52] [53] [54] .
The genome of CHO-K1 cells can also provide insights into less well-characterized phenotypes. For example, the global analysis of viral susceptibility genes in the CHO genome demonstrates that key A r t i c l e s plasma membrane receptor genes, CAMs, and genes involved in T-cell activation and macromolecular assembly are not expressed in CHO-K1. Furthermore, the lack of expression of several key viral entry receptors for HSV-1, HIV, HBV and pseudorabies virus opens up the possibility for an in-depth analysis of CHO cell resistance to viral infection. In addition, we found several key regulatory molecules such as histone factors to be lacking expression in CHO-K1. This analysis demonstrates that the genome sequence can be integrated with ' omic data analysis to generate hypotheses to guide further study into poorly characterized phenotypes of CHO cells (Fig. 5b) .
The CHO-K1 genome should facilitate the interpretation of various ' omic data types. However, it is important to note that CHO-K1 is an ancestral cell line from which many CHO cell lines have been derived. During the course of the rather stringent manipulations involved in optimizing cell lines (e.g., selection for growth in different media compositions and switching cells from adherent cell culture to suspension-adapted growth), many genomic changes (e.g., SNPs, indels and other structural variations) have likely occurred owing to the inherent genomic instability of these cell lines. Moreover, the cell lines derived from CHO-K1 that are widely used in the industry (e.g., DUKX-B11 and DG44) may contain additional genetic changes from chemical and radiation mutagenesis 5, 6 . Thus, this genome sequence of the ancestral K1 cell line should not be considered as completely representative of all CHO cell lines. However, the full coverage draft genomic sequence of the ancestral K1 cell line will serve as a foundation to support efforts in sequencing other CHO cell lines (Fig. 5c) . These additional genomic sequences will provide a context for transcriptomic and proteomic data interpretation in the respective cell lines. It will also facilitate the identification or design of other potential targets or tools for cell line engineering (e.g., microRNAs and short interfering (si)RNAs).
The availability of the CHO-K1 genomic sequence provides a valuable resource for genome-scale CHO-cell research and will aid in manufacturing applications. However, we expect the quality of the genomic sequence will be iteratively improved over time as more genomic information becomes available for CHO-K1 and other CHO cell lines. Moreover, we anticipate that characterizing effects of sequence variations on gene products and expression would improve the functional annotation of these cell lines. These improvements may enhance the application of CHO-cell engineering and other techniques to improve protein production and quality.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/. Accession codes. Sequence Read Archive: SRA040022.1 for assembly raw data and SRA040045.1 for transcriptome. This Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession AFTD00000000. The version described in this paper is the first version, AFTD01000000.
Note: Supplementary information is available on the Nature Biotechnology website. Figure 5 The CHO-K1 genome will aid in cell line engineering, generate hypotheses for biological discovery, and serve as a context to facilitate sequencing efforts and sequence analysis for additional cell lines. Although significant advances in CHO biology have occurred over the past decades, the accessibility of the CHO-K1 genome will have an impact on at least three major areas. (a) The CHO genome will aid cell line engineering by facilitating the application of experimental and computational sequence-based tools for genetic manipulation and genome analysis. For example, BLAST can be used to identify the CHO sequence of a desired gene, whereas siRNA and site-directed mutagenesis methods can be used to directly modulate gene expression levels and protein activities. Moreover, the genome sequence can be used to reconstruct models of CHO-K1 metabolism, which allow the assessment of how genetic manipulations affect other pathways and can predict nonintuitive genetic changes to improve product yield or quality. (b) The biomolecular mechanisms underlying many phenotypic properties of CHO are poorly characterized (e.g., viral susceptibility). The components underlying these phenotypes can be identified through the comparison of CHO gene content and gene expression with other organisms or cell lines. (c) Although large genomic changes can occur in immortalized and engineered cell lines such as CHO, the CHO-K1 genome can serve as a context for the assembly and analysis of genome sequences from additional CHO cell lines. 
